D005472Chemicals & DrugsD03.383.742.698.875.40438719420.70409FluorouracilFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonBreast Medical OncologyGI Medical OncologyRadiation OncologySurgical OncologyMD AndersonJAFFER AAJANIJAFFER A AJANI8473AJANI, JAFFER AProfessorMATTHEW HAROLDKATZMATTHEW HAROLD KATZ9338KATZ, MATTHEW HAROLDAssociate ProfessorAMAN UBUZDARAMAN U BUZDAR8609BUZDAR, AMAN UProfessorCATHYENGCATHY ENG9041ENG, CATHYProfessorBRUCEMINSKYBRUCE MINSKY9819MINSKY, BRUCEProfessor74Professor14Associate Professor6.099020.00396016387research area of0.8136020.00898102930subject area for31804659Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, R?del C, Fokas EJAMA oncologyAssociation of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer. JAMA Oncol. 2020 02 01; 6(2):294-296.JAMA Oncol2020-02-01T00:00:002020Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer.32234665Kim RD, McDonough S, El-Khoueiry AB, Bekaii-Saab TS, Stein SM, Sahai V, Keogh GP, Kim EJ, Baron AD, Siegel AB, Barzi A, Guthrie KA, Javle M, Hochster HEuropean journal of cancer (Oxford, England : 1990)Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. Eur J Cancer. 2020 05; 130:219-227.Eur J Cancer2020-03-29T00:00:002020Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.33338532Sui Q, Peng J, Han K, Lin J, Zhang R, Ou Q, Qin J, Deng Y, Zhou W, Kong L, Tang J, Xiao B, Li Y, Yu L, Fang Y, Ding PR, Pan ZCancer lettersVoltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cancer Lett. 2021 03 01; 500:119-131.Cancer Lett2020-12-16T00:00:002020Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.33434908Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari ANeuroendocrinologyFluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2022; 112(1):34-42.Neuroendocrinology2021-01-12T00:00:002021Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.33965356Leung M, Rogers JE, Shureiqi IClinical colorectal cancerUse of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant. Clin Colorectal Cancer. 2021 09; 20(3):273-278.Clin Colorectal Cancer2021-04-06T00:00:002021Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor